| scholarly article | Q13442814 |
| P2093 | author name string | Toshitaka Nakamura | |
| Masao Fukunaga | |||
| Masataka Shiraki | |||
| Tatsuhiko Kuroda | |||
| Takayuki Hosoi | |||
| Hajime Orimo | |||
| Adequate Treatment of Osteoporosis (A-TOP) Research Group | |||
| Kuniyoshi Makino | |||
| P2860 | cites work | The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis | Q28241336 |
| Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. | Q31921266 | ||
| Risk assessment for osteoporosis. II. Biochemical markers of bone turnover: bone resorption indices | Q34032514 | ||
| Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment | Q34104308 | ||
| Osteoporosis prevention, diagnosis, and therapy | Q34140339 | ||
| Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study | Q34404537 | ||
| Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group | Q34409983 | ||
| Diagnostic criteria for primary osteoporosis: year 2000 revision | Q34422528 | ||
| Epidemiology and predictors of fractures associated with osteoporosis | Q34439769 | ||
| Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial | Q34485941 | ||
| Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force | Q34527169 | ||
| Epidemiology of vertebral osteoporosis | Q35345627 | ||
| Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study | Q36596562 | ||
| Mortality after all major types of osteoporotic fracture in men and women: an observational study. | Q39490012 | ||
| Fracture prediction from bone mineral density in Japanese men and women | Q40567275 | ||
| Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis | Q40768242 | ||
| Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group | Q41672880 | ||
| Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group | Q41697049 | ||
| The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study | Q43800692 | ||
| Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators | Q43988923 | ||
| Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group | Q44126176 | ||
| Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). | Q44309049 | ||
| Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. | Q46234046 | ||
| Sample-size formula for the proportional-hazards regression model | Q47253781 | ||
| Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women | Q47427296 | ||
| Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. | Q51079439 | ||
| Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. | Q52082166 | ||
| Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women | Q70679040 | ||
| Association of bone mineral density with apolipoprotein E phenotype | Q73673405 | ||
| Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study | Q74141058 | ||
| Osteoporosis and fracture risk in women of different ethnic groups | Q81264820 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 219-225 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Journal of Bone and Mineral Metabolism | Q15767236 |
| P1476 | title | The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria: prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteopo | |
| P478 | volume | 24 |
| Q39874235 | Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group |
| Q39903185 | Effects of bone mineral density of the lumbar spine and prevalent vertebral fractures on the risk of immobility |
| Q43134194 | High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment |
| Q40696253 | Impact of Osteonecrosis of the Jaw on Osteoporosis Treatment in Japan: Results of a Questionnaire-Based Survey by the Adequate Treatment of Osteoporosis (A-TOP) Research Group |
| Q46839990 | Low plasma phylloquinone concentration is associated with high incidence of vertebral fracture in Japanese women. |
| Q46839982 | Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures |
| Q47686740 | Restrictive pulmonary dysfunction is associated with vertebral fractures and bone loss in elderly postmenopausal women. |
| Q40030851 | The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures |
| Q39874552 | Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment |
Search more.